Identification and Treatment of the Liability to Develop Schizophrenia

Central South University

Status and phase

Unknown

Phase 4

Conditions

Schizophrenia

Treatments

Drug: Risperidone

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00305474

XYMHI001

Details and patient eligibility

About

This study seeks to determine whether adult, non-psychotic, first-degree relatives of schizophrenic patients who show specific neurocognitive deficits and negative symptoms will show improvements in these areas following a 6-month, double-blind trial of a low dose (up to 2.0 mg) of risperidone.

Enrollment

100 estimated patients

Sex

All

Ages

19 to 59 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Having at least one first-degree biological relative with schizophrenia and their age is between 19 and 59.
Desire to participate in a medication trial.
Is able to provide informed consent.
Having moderate levels of negative symptoms, defined as 6 items rated 3 or higher on the Scale for the Assessment of Negative Symptoms (SANS).
Scoring two or more standard deviations below normal in at least one of three cognitive domains: vigilance/working memory, long-term verbal memory, and executive functions.
Scoring at least one standard deviation below normal in a second cognitive domain.

Exclusion criteria

IQ less than 80.
Formal education less than 10 years.
History of psychotic disorders.
History of treatment with an antipsychotic medication.
A substance abuse diagnosis within 6 months of diagnosis.
A head injury with documented loss of consciousness exceeding 5 minutes (or subsequent cognitive deficits).
A history of neurologic disease or damage.
A medical condition with significant cognitive sequelae.
A history of electroconvulsive treatment.